Graft Versus Host Disease Treatment Market Insights, Global Outlook and Forecast 2022-2028
Graft Versus Host Disease Treatment Market Insights, Global Outlook and Forecast 2022-2028
Insights into the Graft Versus Host Disease Treatment Market include supply chain optimization, Graft Versus Host Disease Treatment challenges, and growth forecasts segmented by region and service type.
Exclusive deal : 20% Instant discount on Direct purchases! Don't wait—claim your discount today!
The latest research study released by Market IntelliX evaluates market size and forecasts of Graft Versus Host Disease Treatment in Global, including the following market information:
Global Graft Versus Host Disease Treatment Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Graft Versus Host Disease Treatment market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period 2022-2028.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Etanercept Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Graft Versus Host Disease Treatment include AbbVie Inc., Acrofan, Astellas Pharma Inc., Bristol-Myers Squibb Company, ElsaLys Biotech SA, F. Hoffmann-La Roche AG, Johnson & Johnson, Mallinckrodft PLC and Merck & Co., Inc., etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MI has surveyed the Graft Versus Host Disease Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Market Segmentations:
Global Graft Versus Host Disease Treatment Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Graft Versus Host Disease Treatment Market Segment Percentages, by Type, 2021 (%)
Etanercept
Monoclonal Antibodies
Thalidomide
Tyrosine Kinase Inhibitors
mTOR Inhibitors
Global Graft Versus Host Disease Treatment Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Graft Versus Host Disease Treatment Market Segment Percentages, by Application, 2021 (%)
Acute GVHD
Chronic GVHD
Prophylaxis GVHD
Global Graft Versus Host Disease Treatment Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Graft Versus Host Disease Treatment Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Graft Versus Host Disease Treatment revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Graft Versus Host Disease Treatment revenues share in global market, 2021 (%)
The report presents profiles of competitors in the market, Some of the prominent key players covered:
AbbVie Inc.
Acrofan
Astellas Pharma Inc.
Bristol-Myers Squibb Company
ElsaLys Biotech SA
F. Hoffmann-La Roche AG
Johnson & Johnson
Mallinckrodft PLC
Merck & Co., Inc.
Mesoblast Limited
Neovii Biotech GmbH
Novartis AG
Ocugen, Inc.
Pfizer Inc
Pluristem Therapeutics Inc.
Samedan Ltd
Sanofi SA
Soligenix, Inc.
Key Takeaways from this Report
Evaluate market potential through analyzing growth rates (CAGR %), Volume (Units) and Value ($M) data given at country level – for product types, end use applications and by different industry verticals.
Understand the different dynamics influencing the market – key driving factors, challenges and hidden opportunities.
Get in-depth insights on your competitor performance – market shares, strategies, financial benchmarking, product benchmarking, SWOT and more.
Analyze the sales and distribution channels across key geographies to improve top-line revenues.
Understand the industry supply chain with a deep-dive on the value augmentation at each step, in order to optimize value and bring efficiencies in your processes.
Get a quick outlook on the market entropy – M&A’s, deals, partnerships, product launches of all key players for the past 4 years.
Evaluate the supply-demand gaps, import-export statistics and regulatory landscape for more than top 20 countries globally for the market.
1 Introduction to Research & Analysis Reports
1.1 Graft Versus Host Disease Treatment Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Graft Versus Host Disease Treatment Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Graft Versus Host Disease Treatment Overall Market Size
2.1 Global Graft Versus Host Disease Treatment Market Size: 2021 VS 2028
2.2 Global Graft Versus Host Disease Treatment Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Graft Versus Host Disease Treatment Players in Global Market
3.2 Top Global Graft Versus Host Disease Treatment Companies Ranked by Revenue
3.3 Global Graft Versus Host Disease Treatment Revenue by Companies
3.4 Top 3 and Top 5 Graft Versus Host Disease Treatment Companies in Global Market, by Revenue in 2021
3.5 Global Companies Graft Versus Host Disease Treatment Product Type
3.6 Tier 1, Tier 2 and Tier 3 Graft Versus Host Disease Treatment Players in Global Market
3.6.1 List of Global Tier 1 Graft Versus Host Disease Treatment Companies
3.6.2 List of Global Tier 2 and Tier 3 Graft Versus Host Disease Treatment Companies
4 Market Sights by Product
4.1 Overview
4.1.1 by Type - Global Graft Versus Host Disease Treatment Market Size Markets, 2021 & 2028
4.1.2 Etanercept
4.1.3 Monoclonal Antibodies
4.1.4 Thalidomide
4.1.5 Tyrosine Kinase Inhibitors
4.1.6 mTOR Inhibitors
4.2 By Type - Global Graft Versus Host Disease Treatment Revenue & Forecasts
4.2.1 By Type - Global Graft Versus Host Disease Treatment Revenue, 2017-2022
4.2.2 By Type - Global Graft Versus Host Disease Treatment Revenue, 2023-2028
4.2.3 By Type - Global Graft Versus Host Disease Treatment Revenue Market Share, 2017-2028
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Graft Versus Host Disease Treatment Market Size, 2021 & 2028
5.1.2 Acute GVHD
5.1.3 Chronic GVHD
5.1.4 Prophylaxis GVHD
5.2 By Application - Global Graft Versus Host Disease Treatment Revenue & Forecasts
5.2.1 By Application - Global Graft Versus Host Disease Treatment Revenue, 2017-2022
5.2.2 By Application - Global Graft Versus Host Disease Treatment Revenue, 2023-2028
5.2.3 By Application - Global Graft Versus Host Disease Treatment Revenue Market Share, 2017-2028
6 Sights by Region
6.1 By Region - Global Graft Versus Host Disease Treatment Market Size, 2021 & 2028
6.2 By Region - Global Graft Versus Host Disease Treatment Revenue & Forecasts
6.2.1 By Region - Global Graft Versus Host Disease Treatment Revenue, 2017-2022
6.2.2 By Region - Global Graft Versus Host Disease Treatment Revenue, 2023-2028
6.2.3 By Region - Global Graft Versus Host Disease Treatment Revenue Market Share, 2017-2028
6.3 North America
6.3.1 By Country - North America Graft Versus Host Disease Treatment Revenue, 2017-2028
6.3.2 US Graft Versus Host Disease Treatment Market Size, 2017-2028
6.3.3 Canada Graft Versus Host Disease Treatment Market Size, 2017-2028
6.3.4 Mexico Graft Versus Host Disease Treatment Market Size, 2017-2028
6.4 Europe
6.4.1 By Country - Europe Graft Versus Host Disease Treatment Revenue, 2017-2028
6.4.2 Germany Graft Versus Host Disease Treatment Market Size, 2017-2028
6.4.3 France Graft Versus Host Disease Treatment Market Size, 2017-2028
6.4.4 U.K. Graft Versus Host Disease Treatment Market Size, 2017-2028
6.4.5 Italy Graft Versus Host Disease Treatment Market Size, 2017-2028
6.4.6 Russia Graft Versus Host Disease Treatment Market Size, 2017-2028
6.4.7 Nordic Countries Graft Versus Host Disease Treatment Market Size, 2017-2028
6.4.8 Benelux Graft Versus Host Disease Treatment Market Size, 2017-2028
6.5 Asia
6.5.1 By Region - Asia Graft Versus Host Disease Treatment Revenue, 2017-2028
6.5.2 China Graft Versus Host Disease Treatment Market Size, 2017-2028
6.5.3 Japan Graft Versus Host Disease Treatment Market Size, 2017-2028
6.5.4 South Korea Graft Versus Host Disease Treatment Market Size, 2017-2028
6.5.5 Southeast Asia Graft Versus Host Disease Treatment Market Size, 2017-2028
6.5.6 India Graft Versus Host Disease Treatment Market Size, 2017-2028
6.6 South America
6.6.1 By Country - South America Graft Versus Host Disease Treatment Revenue, 2017-2028
6.6.2 Brazil Graft Versus Host Disease Treatment Market Size, 2017-2028
6.6.3 Argentina Graft Versus Host Disease Treatment Market Size, 2017-2028
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Graft Versus Host Disease Treatment Revenue, 2017-2028
6.7.2 Turkey Graft Versus Host Disease Treatment Market Size, 2017-2028
6.7.3 Israel Graft Versus Host Disease Treatment Market Size, 2017-2028
6.7.4 Saudi Arabia Graft Versus Host Disease Treatment Market Size, 2017-2028
6.7.5 UAE Graft Versus Host Disease Treatment Market Size, 2017-2028
7 Players Profiles
7.1 AbbVie Inc.
7.1.1 AbbVie Inc. Corporate Summary
7.1.2 AbbVie Inc. Business Overview
7.1.3 AbbVie Inc. Graft Versus Host Disease Treatment Major Product Offerings
7.1.4 AbbVie Inc. Graft Versus Host Disease Treatment Revenue in Global Market (2017-2022)
7.1.5 AbbVie Inc. Key News
7.2 Acrofan
7.2.1 Acrofan Corporate Summary
7.2.2 Acrofan Business Overview
7.2.3 Acrofan Graft Versus Host Disease Treatment Major Product Offerings
7.2.4 Acrofan Graft Versus Host Disease Treatment Revenue in Global Market (2017-2022)
7.2.5 Acrofan Key News
7.3 Astellas Pharma Inc.
7.3.1 Astellas Pharma Inc. Corporate Summary
7.3.2 Astellas Pharma Inc. Business Overview
7.3.3 Astellas Pharma Inc. Graft Versus Host Disease Treatment Major Product Offerings
7.3.4 Astellas Pharma Inc. Graft Versus Host Disease Treatment Revenue in Global Market (2017-2022)
7.3.5 Astellas Pharma Inc. Key News
7.4 Bristol-Myers Squibb Company
7.4.1 Bristol-Myers Squibb Company Corporate Summary
7.4.2 Bristol-Myers Squibb Company Business Overview
7.4.3 Bristol-Myers Squibb Company Graft Versus Host Disease Treatment Major Product Offerings
7.4.4 Bristol-Myers Squibb Company Graft Versus Host Disease Treatment Revenue in Global Market (2017-2022)
7.4.5 Bristol-Myers Squibb Company Key News
7.5 ElsaLys Biotech SA
7.5.1 ElsaLys Biotech SA Corporate Summary
7.5.2 ElsaLys Biotech SA Business Overview
7.5.3 ElsaLys Biotech SA Graft Versus Host Disease Treatment Major Product Offerings
7.5.4 ElsaLys Biotech SA Graft Versus Host Disease Treatment Revenue in Global Market (2017-2022)
7.5.5 ElsaLys Biotech SA Key News
7.6 F. Hoffmann-La Roche AG
7.6.1 F. Hoffmann-La Roche AG Corporate Summary
7.6.2 F. Hoffmann-La Roche AG Business Overview
7.6.3 F. Hoffmann-La Roche AG Graft Versus Host Disease Treatment Major Product Offerings
7.6.4 F. Hoffmann-La Roche AG Graft Versus Host Disease Treatment Revenue in Global Market (2017-2022)
7.6.5 F. Hoffmann-La Roche AG Key News
7.7 Johnson & Johnson
7.7.1 Johnson & Johnson Corporate Summary
7.7.2 Johnson & Johnson Business Overview
7.7.3 Johnson & Johnson Graft Versus Host Disease Treatment Major Product Offerings
7.7.4 Johnson & Johnson Graft Versus Host Disease Treatment Revenue in Global Market (2017-2022)
7.7.5 Johnson & Johnson Key News
7.8 Mallinckrodft PLC
7.8.1 Mallinckrodft PLC Corporate Summary
7.8.2 Mallinckrodft PLC Business Overview
7.8.3 Mallinckrodft PLC Graft Versus Host Disease Treatment Major Product Offerings
7.8.4 Mallinckrodft PLC Graft Versus Host Disease Treatment Revenue in Global Market (2017-2022)
7.8.5 Mallinckrodft PLC Key News
7.9 Merck & Co., Inc.
7.9.1 Merck & Co., Inc. Corporate Summary
7.9.2 Merck & Co., Inc. Business Overview
7.9.3 Merck & Co., Inc. Graft Versus Host Disease Treatment Major Product Offerings
7.9.4 Merck & Co., Inc. Graft Versus Host Disease Treatment Revenue in Global Market (2017-2022)
7.9.5 Merck & Co., Inc. Key News
7.10 Mesoblast Limited
7.10.1 Mesoblast Limited Corporate Summary
7.10.2 Mesoblast Limited Business Overview
7.10.3 Mesoblast Limited Graft Versus Host Disease Treatment Major Product Offerings
7.10.4 Mesoblast Limited Graft Versus Host Disease Treatment Revenue in Global Market (2017-2022)
7.10.5 Mesoblast Limited Key News
7.11 Neovii Biotech GmbH
7.11.1 Neovii Biotech GmbH Corporate Summary
7.11.2 Neovii Biotech GmbH Business Overview
7.11.3 Neovii Biotech GmbH Graft Versus Host Disease Treatment Major Product Offerings
7.11.4 Neovii Biotech GmbH Graft Versus Host Disease Treatment Revenue in Global Market (2017-2022)
7.11.5 Neovii Biotech GmbH Key News
7.12 Novartis AG
7.12.1 Novartis AG Corporate Summary
7.12.2 Novartis AG Business Overview
7.12.3 Novartis AG Graft Versus Host Disease Treatment Major Product Offerings
7.12.4 Novartis AG Graft Versus Host Disease Treatment Revenue in Global Market (2017-2022)
7.12.5 Novartis AG Key News
7.13 Ocugen, Inc.
7.13.1 Ocugen, Inc. Corporate Summary
7.13.2 Ocugen, Inc. Business Overview
7.13.3 Ocugen, Inc. Graft Versus Host Disease Treatment Major Product Offerings
7.13.4 Ocugen, Inc. Graft Versus Host Disease Treatment Revenue in Global Market (2017-2022)
7.13.5 Ocugen, Inc. Key News
7.14 Pfizer Inc
7.14.1 Pfizer Inc Corporate Summary
7.14.2 Pfizer Inc Business Overview
7.14.3 Pfizer Inc Graft Versus Host Disease Treatment Major Product Offerings
7.14.4 Pfizer Inc Graft Versus Host Disease Treatment Revenue in Global Market (2017-2022)
7.14.5 Pfizer Inc Key News
7.15 Pluristem Therapeutics Inc.
7.15.1 Pluristem Therapeutics Inc. Corporate Summary
7.15.2 Pluristem Therapeutics Inc. Business Overview
7.15.3 Pluristem Therapeutics Inc. Graft Versus Host Disease Treatment Major Product Offerings
7.15.4 Pluristem Therapeutics Inc. Graft Versus Host Disease Treatment Revenue in Global Market (2017-2022)
7.15.5 Pluristem Therapeutics Inc. Key News
7.16 Samedan Ltd
7.16.1 Samedan Ltd Corporate Summary
7.16.2 Samedan Ltd Business Overview
7.16.3 Samedan Ltd Graft Versus Host Disease Treatment Major Product Offerings
7.16.4 Samedan Ltd Graft Versus Host Disease Treatment Revenue in Global Market (2017-2022)
7.16.5 Samedan Ltd Key News
7.17 Sanofi SA
7.17.1 Sanofi SA Corporate Summary
7.17.2 Sanofi SA Business Overview
7.17.3 Sanofi SA Graft Versus Host Disease Treatment Major Product Offerings
7.17.4 Sanofi SA Graft Versus Host Disease Treatment Revenue in Global Market (2017-2022)
7.17.5 Sanofi SA Key News
7.18 Soligenix, Inc.
7.18.1 Soligenix, Inc. Corporate Summary
7.18.2 Soligenix, Inc. Business Overview
7.18.3 Soligenix, Inc. Graft Versus Host Disease Treatment Major Product Offerings
7.18.4 Soligenix, Inc. Graft Versus Host Disease Treatment Revenue in Global Market (2017-2022)
7.18.5 Soligenix, Inc. Key News
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
List of Tables
Table 1. Graft Versus Host Disease Treatment Market Opportunities & Trends in Global Market
Table 2. Graft Versus Host Disease Treatment Market Drivers in Global Market
Table 3. Graft Versus Host Disease Treatment Market Restraints in Global Market
Table 4. Key Players of Graft Versus Host Disease Treatment in Global Market
Table 5. Top Graft Versus Host Disease Treatment Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Graft Versus Host Disease Treatment Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Graft Versus Host Disease Treatment Revenue Share by Companies, 2017-2022
Table 8. Global Companies Graft Versus Host Disease Treatment Product Type
Table 9. List of Global Tier 1 Graft Versus Host Disease Treatment Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Graft Versus Host Disease Treatment Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Graft Versus Host Disease Treatment Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Graft Versus Host Disease Treatment Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Graft Versus Host Disease Treatment Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global Graft Versus Host Disease Treatment Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Graft Versus Host Disease Treatment Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Graft Versus Host Disease Treatment Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Graft Versus Host Disease Treatment Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Graft Versus Host Disease Treatment Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Graft Versus Host Disease Treatment Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Graft Versus Host Disease Treatment Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Graft Versus Host Disease Treatment Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Graft Versus Host Disease Treatment Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Graft Versus Host Disease Treatment Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Graft Versus Host Disease Treatment Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Graft Versus Host Disease Treatment Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Graft Versus Host Disease Treatment Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Graft Versus Host Disease Treatment Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Graft Versus Host Disease Treatment Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Graft Versus Host Disease Treatment Revenue, (US$, Mn), 2023-2028
Table 30. AbbVie Inc. Corporate Summary
Table 31. AbbVie Inc. Graft Versus Host Disease Treatment Product Offerings
Table 32. AbbVie Inc. Graft Versus Host Disease Treatment Revenue (US$, Mn), (2017-2022)
Table 33. Acrofan Corporate Summary
Table 34. Acrofan Graft Versus Host Disease Treatment Product Offerings
Table 35. Acrofan Graft Versus Host Disease Treatment Revenue (US$, Mn), (2017-2022)
Table 36. Astellas Pharma Inc. Corporate Summary
Table 37. Astellas Pharma Inc. Graft Versus Host Disease Treatment Product Offerings
Table 38. Astellas Pharma Inc. Graft Versus Host Disease Treatment Revenue (US$, Mn), (2017-2022)
Table 39. Bristol-Myers Squibb Company Corporate Summary
Table 40. Bristol-Myers Squibb Company Graft Versus Host Disease Treatment Product Offerings
Table 41. Bristol-Myers Squibb Company Graft Versus Host Disease Treatment Revenue (US$, Mn), (2017-2022)
Table 42. ElsaLys Biotech SA Corporate Summary
Table 43. ElsaLys Biotech SA Graft Versus Host Disease Treatment Product Offerings
Table 44. ElsaLys Biotech SA Graft Versus Host Disease Treatment Revenue (US$, Mn), (2017-2022)
Table 45. F. Hoffmann-La Roche AG Corporate Summary
Table 46. F. Hoffmann-La Roche AG Graft Versus Host Disease Treatment Product Offerings
Table 47. F. Hoffmann-La Roche AG Graft Versus Host Disease Treatment Revenue (US$, Mn), (2017-2022)
Table 48. Johnson & Johnson Corporate Summary
Table 49. Johnson & Johnson Graft Versus Host Disease Treatment Product Offerings
Table 50. Johnson & Johnson Graft Versus Host Disease Treatment Revenue (US$, Mn), (2017-2022)
Table 51. Mallinckrodft PLC Corporate Summary
Table 52. Mallinckrodft PLC Graft Versus Host Disease Treatment Product Offerings
Table 53. Mallinckrodft PLC Graft Versus Host Disease Treatment Revenue (US$, Mn), (2017-2022)
Table 54. Merck & Co., Inc. Corporate Summary
Table 55. Merck & Co., Inc. Graft Versus Host Disease Treatment Product Offerings
Table 56. Merck & Co., Inc. Graft Versus Host Disease Treatment Revenue (US$, Mn), (2017-2022)
Table 57. Mesoblast Limited Corporate Summary
Table 58. Mesoblast Limited Graft Versus Host Disease Treatment Product Offerings
Table 59. Mesoblast Limited Graft Versus Host Disease Treatment Revenue (US$, Mn), (2017-2022)
Table 60. Neovii Biotech GmbH Corporate Summary
Table 61. Neovii Biotech GmbH Graft Versus Host Disease Treatment Product Offerings
Table 62. Neovii Biotech GmbH Graft Versus Host Disease Treatment Revenue (US$, Mn), (2017-2022)
Table 63. Novartis AG Corporate Summary
Table 64. Novartis AG Graft Versus Host Disease Treatment Product Offerings
Table 65. Novartis AG Graft Versus Host Disease Treatment Revenue (US$, Mn), (2017-2022)
Table 66. Ocugen, Inc. Corporate Summary
Table 67. Ocugen, Inc. Graft Versus Host Disease Treatment Product Offerings
Table 68. Ocugen, Inc. Graft Versus Host Disease Treatment Revenue (US$, Mn), (2017-2022)
Table 69. Pfizer Inc Corporate Summary
Table 70. Pfizer Inc Graft Versus Host Disease Treatment Product Offerings
Table 71. Pfizer Inc Graft Versus Host Disease Treatment Revenue (US$, Mn), (2017-2022)
Table 72. Pluristem Therapeutics Inc. Corporate Summary
Table 73. Pluristem Therapeutics Inc. Graft Versus Host Disease Treatment Product Offerings
Table 74. Pluristem Therapeutics Inc. Graft Versus Host Disease Treatment Revenue (US$, Mn), (2017-2022)
Table 75. Samedan Ltd Corporate Summary
Table 76. Samedan Ltd Graft Versus Host Disease Treatment Product Offerings
Table 77. Samedan Ltd Graft Versus Host Disease Treatment Revenue (US$, Mn), (2017-2022)
Table 78. Sanofi SA Corporate Summary
Table 79. Sanofi SA Graft Versus Host Disease Treatment Product Offerings
Table 80. Sanofi SA Graft Versus Host Disease Treatment Revenue (US$, Mn), (2017-2022)
Table 81. Soligenix, Inc. Corporate Summary
Table 82. Soligenix, Inc. Graft Versus Host Disease Treatment Product Offerings
Table 83. Soligenix, Inc. Graft Versus Host Disease Treatment Revenue (US$, Mn), (2017-2022)
List of Figures
Figure 1. Graft Versus Host Disease Treatment Segment by Type in 2021
Figure 2. Graft Versus Host Disease Treatment Segment by Application in 2021
Figure 3. Global Graft Versus Host Disease Treatment Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Graft Versus Host Disease Treatment Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Graft Versus Host Disease Treatment Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Graft Versus Host Disease Treatment Revenue in 2021
Figure 8. By Type - Global Graft Versus Host Disease Treatment Revenue Market Share, 2017-2028
Figure 9. By Application - Global Graft Versus Host Disease Treatment Revenue Market Share, 2017-2028
Figure 10. By Region - Global Graft Versus Host Disease Treatment Revenue Market Share, 2017-2028
Figure 11. By Country - North America Graft Versus Host Disease Treatment Revenue Market Share, 2017-2028
Figure 12. US Graft Versus Host Disease Treatment Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Graft Versus Host Disease Treatment Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Graft Versus Host Disease Treatment Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Graft Versus Host Disease Treatment Revenue Market Share, 2017-2028
Figure 16. Germany Graft Versus Host Disease Treatment Revenue, (US$, Mn), 2017-2028
Figure 17. France Graft Versus Host Disease Treatment Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Graft Versus Host Disease Treatment Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Graft Versus Host Disease Treatment Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Graft Versus Host Disease Treatment Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Graft Versus Host Disease Treatment Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Graft Versus Host Disease Treatment Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Graft Versus Host Disease Treatment Revenue Market Share, 2017-2028
Figure 24. China Graft Versus Host Disease Treatment Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Graft Versus Host Disease Treatment Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Graft Versus Host Disease Treatment Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Graft Versus Host Disease Treatment Revenue, (US$, Mn), 2017-2028
Figure 28. India Graft Versus Host Disease Treatment Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Graft Versus Host Disease Treatment Revenue Market Share, 2017-2028
Figure 30. Brazil Graft Versus Host Disease Treatment Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Graft Versus Host Disease Treatment Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Graft Versus Host Disease Treatment Revenue Market Share, 2017-2028
Figure 33. Turkey Graft Versus Host Disease Treatment Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Graft Versus Host Disease Treatment Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Graft Versus Host Disease Treatment Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Graft Versus Host Disease Treatment Revenue, (US$, Mn), 2017-2028
Figure 37. AbbVie Inc. Graft Versus Host Disease Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Acrofan Graft Versus Host Disease Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Astellas Pharma Inc. Graft Versus Host Disease Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Bristol-Myers Squibb Company Graft Versus Host Disease Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. ElsaLys Biotech SA Graft Versus Host Disease Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. F. Hoffmann-La Roche AG Graft Versus Host Disease Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Johnson & Johnson Graft Versus Host Disease Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Mallinckrodft PLC Graft Versus Host Disease Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. Merck & Co., Inc. Graft Versus Host Disease Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 46. Mesoblast Limited Graft Versus Host Disease Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 47. Neovii Biotech GmbH Graft Versus Host Disease Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 48. Novartis AG Graft Versus Host Disease Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 49. Ocugen, Inc. Graft Versus Host Disease Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 50. Pfizer Inc Graft Versus Host Disease Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 51. Pluristem Therapeutics Inc. Graft Versus Host Disease Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 52. Samedan Ltd Graft Versus Host Disease Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 53. Sanofi SA Graft Versus Host Disease Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 54. Soligenix, Inc. Graft Versus Host Disease Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Research Methodology:
Graft Versus Host Disease Treatment Market Size Estimation
To estimate market size and trends, we use a combination of top-down and bottom-up methods. This allows us to evaluate the market from various perspectives—by company, region, product type, and end users.
Our estimates are based on actual sales data, excluding any discounts. Segment breakdowns and market shares are calculated using weighted averages based on usage rates and average prices. Regional insights are determined by how widely a product or service is adopted in each area.
Key companies are identified through secondary sources like industry reports and company filings. We then verify revenue estimates and other key data points through primary research, including interviews with industry experts, company executives, and decision-makers.
We take into account all relevant factors that could influence the market and validate our findings with real-world input. Our final insights combine both qualitative and quantitative data to provide a well-rounded view. Please note, these estimates do not account for unexpected changes such as inflation, economic downturns, or policy shifts.
Data Source
Secondary Sources
This study draws on a wide range of secondary sources, including press releases, annual reports, non-profit organizations, industry associations, government agencies, and customs data. We also referred to reputable databases and directories such as Bloomberg, Wind Info, Hoovers, Factiva, Trading Economics, Statista, and others. Additional references include investor presentations, company filings (e.g., SEC), economic data, and documents from regulatory and industry bodies.
These sources were used to gather technical and market-focused insights, identify key players, analyze market segmentation and classification, and track major trends and developments across industries.
| Market Size |
|
|
| Market Position of Top Company |
|
|
| Qualitative Analysis |
|
|
Primary Sources
As part of our primary research, we interviewed a variety of stakeholders from both the supply and demand sides to gather valuable qualitative and quantitative insights.
On the supply side, we spoke with product manufacturers, competitors, industry experts, research institutions, distributors, traders, and raw material suppliers. On the demand side, we engaged with business leaders, marketing and sales heads, technology and innovation directors, supply chain executives, and end users across key organizations.
These conversations helped us better understand market segmentation, pricing, applications, leading players, supply chains, demand trends, industry outlook, and key market dynamics—including risks, opportunities, barriers, and strategic developments.
Key Data Information from Primary Sources
| Primary Sources | Parameters | Key Data |
| Market Segments(by Application, by Type) |
|
|
| Total Market |
|
|